Cellular and Extracellular Vesicle RNA Analysis in the Global Threat Fungus Candida auris

Microbiol Spectr. 2021 Dec 22;9(3):e0153821. doi: 10.1128/Spectrum.01538-21. Epub 2021 Dec 15.

Abstract

Emerging and reemerging pathogens are a worldwide concern, and it is predicted that these microbes will cause severe outbreaks. Candida auris affects people with weakened immune systems, particularly those who are hospitalized or are in health care facilities. Extracellular vesicles (EVs) are lipid bilayer structures released by organisms from all domains of life. EVs can deliver functional molecules to target cells, including proteins and nucleic acids, especially RNA molecules. EVs from several pathogenic fungi species play diverse biological roles related to cell-cell communication and pathogen-host interaction. In this study, we describe a data set which we produced by sequencing the RNA content of EVs from C. auris under normal growth conditions and in the presence of the antifungal caspofungin, a first-line drug to treat this fungus. To generate a more complete data set for future comparative studies, we also sequenced the RNA cellular content of EVs under the same conditions. This data set addresses a previously unexplored area of fungal biology regarding cellular small RNA and EV RNA. Our data will provide a molecular basis for the study of the aspects associated with antifungal treatment, gene expression response, and EV composition in C. auris. These data will also allow the exploration of small RNA content in the fungal kingdom and might serve as an informative basis for studies on the mechanisms by which molecules are directed to fungal EVs. IMPORTANCE Candida auris, a relevant emerging human-pathogenic yeast, is the first fungus to be called a global public health threat by the WHO. This is because of its rapid spread on all inhabited continents, together with its extremely high frequency of drug and multidrug resistance. In our study, we generated a large data set for 3 distinct strains of C. auris and obtained cellular small RNA fraction as well as extracellular vesicle RNA (EV-RNA) during normal growth conditions and after treatment with caspofungin, the first-line drug used to treat C. auris infection.

Keywords: Candida auris; RNA-seq; dataset; extracellular vesicles; small RNA.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Candida auris / drug effects*
  • Candida auris / genetics
  • Candida auris / metabolism*
  • Candidiasis, Invasive / drug therapy
  • Diagnostic Tests, Routine
  • Extracellular Vesicles / metabolism*
  • Fungi / genetics
  • Genetic Techniques
  • Host-Pathogen Interactions
  • Humans
  • Microbial Sensitivity Tests
  • RNA / metabolism*

Substances

  • Antifungal Agents
  • RNA

Supplementary concepts

  • Candida auris infection